Find a Research Study
Prader-Willi Syndrome (PWS)
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
Pragmatic Pediatric Trial of Balanced vs. Normal Saline Fluid in Sepsis (PRoMPT BOLUS)
To find out which of two commonly used IV fluids given in the Emergency Department for sepsis is most effective.
ProMetic BioTherapeutics Immune Globulin Intravenous (PBT IVIG Protocol 2004C009G)
Two main purposes of the study: To see if serious bacterial infections occur less than once a year in each study subject. This will determine if study drug is effective. Also to find out if study drug is safe and tolerable for study subjects.
Remodulin for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN)
To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.
Safety of UCB-MNC Delivered into the Myocardium in HLHS Subjects
To determine the safety and feasibility of autologous umbilical cord blood-derived mononuclear cells delivered into the myocardium of the right ventricle during planned Stage II Glen surgical procedure for individuals with hypoplastic left heart syndrome.
Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.
Tumor Registry
The primary aim of this registry will be to identify genes and/or biologic and environmental factors that either cause these tumors or increase one's risk for developing them. Ultimately, research using this registry may result in improved diagnosis, more effective treatments and possibly prevention.
Vascular Function in Children
The objective of this study is to better understand the effects of chronic diseases, such as congenital heart disease, on blood vessel function and on blood characteristics.
Xeltis Bioabsorbable Pulmonary Valved Conduit Early Feasibility Study
To assess the survival rate of subjects at 6 and 12 months following implantation of the Bioabsorbable pulmonary valve conduit. To assess the rate of conduit failures at 6 months, requiring re-intervention or reoperation.